Department of Emergency and Hospital Medicine, Lehigh Valley Hospital-Cedar Crest, Allentown, PA; Morsani College of Medicine, University of South Florida, Tampa, FL.
Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA.
Curr Probl Cardiol. 2022 Oct;47(10):100993. doi: 10.1016/j.cpcardiol.2021.100993. Epub 2021 Sep 24.
There are limited data on clinical outcomes in patients re-admitted with decompensated heart failure (HF) with concomitant liver cirrhosis. We conducted a cross sectional analysis of the Nationwide Readmissions Database (NRD) years 2010 thru 2012. An Index admission was defined as a hospitalization for decompensated heart failure among persons aged ≥ 18 years with an alive discharge status. The main outcome was 30 - day all-cause rehospitalization. Survey logistic regression provided the unadjusted and adjusted odds of 30 - day rehospitalization among persons with and without cirrhosis, accounting for age, gender, kidney dysfunction and other comorbidities. There were 2,147,363 heart failure (HF) hospitalizations among which 26,156 (1.2%) had comorbid cirrhosis. Patients with cirrhosis were more likely to have a diagnosis of acute kidney injury (AKI) during their index hospitalization (18.4% vs 15.2%). There were 469,111 (21.9%) patients with readmission within 30 - days. The adjusted odds of a 30 - day readmission was significantly higher among patients with cirrhosis compared to without after adjusting for comorbid conditions (adjusted Odds Ratio [aOR], 1.3; 95% Confidence Interval [CI}: 1.2 to 1.4). The relative risk of 30 - day readmission among those with cirrhosis but without renal disease (aOR, 1.3; 95% CI: 1.3 to 1.3) was lower than those with both cirrhosis and renal disease (aOR, 1.8; 95% CI: 1.6 to 2.0) when compared to persons without either comorbidities. Risk of 30 - day rehospitalization was significantly higher among patients with heart failure and underlying cirrhosis. Concurrent renal dysfunction among patients with cirrhosis hospitalized for decompensated HF was associated with a greater odds of rehospitalization.
在伴有肝硬化的失代偿性心力衰竭(HF)患者再次入院的临床结果方面,数据有限。我们对 2010 年至 2012 年的全国再入院数据库(NRD)进行了横断面分析。索引入院定义为年龄≥18 岁的失代偿性心力衰竭患者的住院治疗,出院时存活。主要结果是 30 天全因再入院。调查逻辑回归提供了有无肝硬化患者 30 天再入院的未调整和调整比值比,考虑了年龄、性别、肾功能障碍和其他合并症。共有 2147363 例心力衰竭(HF)住院患者,其中 26156 例(1.2%)合并肝硬化。肝硬化患者在其指数住院期间更有可能被诊断为急性肾损伤(AKI)(18.4%比 15.2%)。在 30 天内有 469111 例(21.9%)患者再次入院。在调整了合并症后,肝硬化患者 30 天内再入院的调整比值比明显高于无肝硬化患者(调整比值比[aOR],1.3;95%置信区间[CI]:1.2 至 1.4)。与无肾脏疾病的肝硬化患者相比(aOR,1.3;95%CI:1.3 至 1.3),伴有肝硬化和肾脏疾病的患者(aOR,1.8;95%CI:1.6 至 2.0)30 天内再入院的相对风险较低。与无任何合并症的患者相比,患有心力衰竭和潜在肝硬化的患者 30 天内再住院的风险显著更高。肝硬化失代偿性 HF 住院患者并发肾功能不全与再住院的可能性增加相关。